Show simple item record

dc.contributor.authorClark, SR
dc.contributor.authorSchubert, KO
dc.contributor.authorOlagunju, AT
dc.contributor.authorLyrtzis, EA
dc.contributor.authorBaune, BT
dc.date.accessioned2020-12-10T00:42:28Z
dc.date.available2020-12-10T00:42:28Z
dc.date.issued2018-12-03
dc.identifier.citationClark, S. R., Schubert, K. O., Olagunju, A. T., Lyrtzis, E. A. & Baune, B. T. (2018). Cognitive and Functional Assessment of Psychosis Stratification Study (CoFAPSS): Rationale, Design, and Characteristics. FRONTIERS IN PSYCHIATRY, 9, https://doi.org/10.3389/fpsyt.2018.00662.
dc.identifier.issn1664-0640
dc.identifier.urihttp://hdl.handle.net/11343/253552
dc.description.abstractPrediction of treatment response and illness trajectory in psychotic disorders including schizophrenia, bipolar affective disorder, schizoaffective disorder, and psychotic depression is difficult due to heterogeneity in presentation and outcome. Consequently, patients may receive prolonged ineffective treatments leading to functional decline, illness chronicity, and iatrogenic physical illness. One approach to addressing these problems is to stratify patients based on historical, clinical, and biological signatures. Such an approach has the potential to improve categorization resulting in better understanding of underlying mechanisms and earlier evidence-based treatment with reduced side effect burden. To investigate these multimodal signatures we developed the Cognitive and Functional Assessment of Psychosis Stratification Study (CoFAPSS) employing a prospective study design and a healthy control group comparison. The main aim of this study is to investigate cognitive, and biological "genomics" markers of psychotic illnesses that can be integrated with clinical data to improve prediction of risk and define functional trajectories. We also aim to identify biological "genomic" signatures underpinning variation in treatment response and adverse medical outcomes. The study commenced in June 2016, including patients with primary diagnosis of psychotic disorders including schizophrenia, bipolar affective disorder, schizoaffective disorder, and psychotic depression according to DSM-5 criteria. The assessment covers a wide range of participant history (life stressors, trauma, and family history), cognitive dimensions (social perception, memory and learning, attention, executive function, and general cognition), measures to assess psychosocial function and quality of life, psychotic symptom severity, clinical course of illness, and parameters for adverse medical outcome. Blood is collected for comprehensive genomic discovery analyses of biological (genomic, transcriptomic, proteomic, and cell-biologic) markers. The CoFAPSS is a novel approach that integrates clinical, cognitive and biological "genomic" markers to clarify clinico-pathological basis of risk, functional trajectories, disease stratification, treatment response, and adverse medical outcome. The CoFAPSS team welcomes collaborations with both national and international investigators.
dc.languageEnglish
dc.publisherFRONTIERS MEDIA SA
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleCognitive and Functional Assessment of Psychosis Stratification Study (CoFAPSS): Rationale, Design, and Characteristics
dc.typeJournal Article
dc.identifier.doi10.3389/fpsyt.2018.00662
melbourne.affiliation.departmentPsychiatry
melbourne.source.titleFrontiers in Psychiatry
melbourne.source.volume9
dc.rights.licenseCC BY
melbourne.elementsid1360918
melbourne.contributor.authorBaune, Bernhard
dc.identifier.eissn1664-0640
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record